(From left) Puneet Anand, Affiliate Vice President and Vertical Head – Company Affairs and Company Communication, Hyundai Motor India Ltd; CS Gopala Krishnan, CMO, Hyundai Motor India Restricted and Trustee, Hyundai Motor India Basis; V. Kamakoti, Director, IIT Madras; and S. Mahalingam, Professor-in-Cost, Hyundai Centre for Most cancers Genomics, IIT Madras, on the launch of the Bharat Most cancers Genome Grid at IIT Madras in Chennai on Wednesday, February 4, 2026.
| Picture Credit score:
BIJOY GHOSH
IIT Madras on Wednesday introduced the Indian most cancers (leukaemia, colorectal and pancreatic) genome sequence era. It additionally made this database publicly accessible at bcga.iitm.ac.in to researchers and clinicians in India and overseas.
S Mahalingam, Professor-In-Cost, Hyundai Centre for Most cancers Genomics, IIT Madras, mentioned the centre had obtained a sequence of round 1,500 most cancers tissue samples from hospitals like Manipal, MMC, Rajiv Gandhi Authorities Hospital, Baby Belief Hospital and JIPMER.
Breast Most cancers Mutation
It was discovered that in breast most cancers, there’s a mutation in a gene referred to as RECQL, which is exclusive to the Indian inhabitants. This implies a lot of the Indian inhabitants has a excessive proportion of this mutation, which was seen within the different inhabitants.
“Regardless of the remedy right this moment is offered, it’s all developed towards western inhabitants. That’s the reason we’re not in a position to see the equal quantity of success knowledge survival fee. There are unwanted side effects too. We don’t have any genome database. That is among the causes we initiated this for the final 5 years,” he mentioned.
Bharat Most cancers Undertaking
The Bharat Most cancers Genome Grid (BCG2) venture, which obtained help from Hyundai beneath its flagship Hyundai Hope for Most cancers initiative, is a clinician-centric nationwide initiative designed to speed up the adoption of Complete Genome Sequencing in routine oncology apply, he mentioned.
Conceived as a useful and scientific adjunct to the Bharat Most cancers Genome Atlas (BCGA), BCG2 goals to bridge the important hole between large-scale most cancers genome knowledge era and its significant utility on the affected person bedside, he added.
Personalised Remedy Increase
IIT Madras Director V Kamakoti mentioned this was an vital initiative that may assist in offering personalised remedy to most cancers sufferers.
“By supporting genomic analysis, early detection, and entry to remedy for underprivileged households, we purpose to strengthen India’s basis for precision oncology and produce hope to numerous youngsters and households impacted by most cancers,” mentioned CS Gopala Krishnan CS, Complete Time Director and Chief Manufacturing Officer, Hyundai Motor & Trustee, HMIF.
Revealed on February 4, 2026
